Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03589339 · ClinicalTrials.gov registry record · Phase 1

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

A Phase 1 study of Metastatic Renal Cell Carcinoma and Squamous Cell Carcinoma of Head and Neck, sponsored by Nanobiotix.

Active
Registry status
Phase 1
Development phase
145
Enrollment target
13
Study locations

NCT03589339 is a Phase 1 study of Metastatic Renal Cell Carcinoma and Squamous Cell Carcinoma of Head and Neck that is active but no longer recruiting, run by Nanobiotix. The registered enrollment target is 145 participants, roughly in line with the 139-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target. The trial reports 13 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03589339, a Phase 1 study of Metastatic Renal Cell Carcinoma and Squamous Cell Carcinoma of Head and Neck, is active but no longer recruiting, sponsored by Nanobiotix.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
145 participants
Enrollment target
13
Study locations

Study Summary

The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.

Conditions Studied

Metastatic Renal Cell Carcinoma Squamous Cell Carcinoma of Head and Neck Metastatic Triple-Negative Breast Carcinoma Immunotherapy Radiotherapy Microsatellite Instability-High Solid Malignant Tumour Metastasis From Malignant Tumor of Liver Metastasis From Malignant Tumor of Cervix Metastasis From Malignant Melanoma of Skin (Disorder) Metastatic NSCLC

Interventions

  • DRUG Pembrolizumab
  • DRUG Nivolumab
  • RADIATION SABR
  • DRUG NBTXR3

Study Locations (13)

Michigan

  • Karmanos Cancer Institute - Detroit
  • Henry Ford Cancer Institute - Detroit

California

  • University of California San Francisco - San Francisco

Florida

  • Moffitt Cancer Center - Tampa

Georgia

  • Emory University - Atlanta

Illinois

  • University of Chicago Medical Center - Chicago

Maryland

  • Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center - Baltimore

New Mexico

  • Christus St. Vincent Regional Cancer Center - Santa Fe

New York

  • Northwell Health - Manhasset

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2019-01-16
Est. Completion 2027-08-30
Phase Phase 1

Sponsor

Nanobiotix

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03589339

The ClinicalTrials.gov registry entry for NCT03589339 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 139-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target. The listed sponsor is Nanobiotix, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT03589339 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Michigan, California, Florida.

Frequently Asked Questions

What is clinical trial NCT03589339 about?

NCT03589339 is a clinical study titled "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy". The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.

What is the current status of trial NCT03589339?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2019-01-16. Estimated completion is 2027-08-30.

What conditions does trial NCT03589339 study?

This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Metastatic Triple-Negative Breast Carcinoma, Immunotherapy, Radiotherapy.

What interventions are being tested in trial NCT03589339?

The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), SABR (RADIATION), NBTXR3 (DRUG).

Who is sponsoring clinical trial NCT03589339?

This trial is sponsored by Nanobiotix, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03589339 being conducted?

This trial has 13 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Renal Cell Carcinoma

All registered trials for this condition

Squamous Cell Carcinoma of Head and Neck

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.